Get the Stockscreener App
1.025
24.25%
-0.315
Humacyte Inc stock is traded at $1.025, with a volume of 20.02M.
It is down -24.25% in the last 24 hours and up +1.50% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.34
Open:
$1.05
24h Volume:
20.02M
Relative Volume:
2.64
Market Cap:
$227.57M
Revenue:
$2.02M
Net Income/Loss:
$-97.59M
P/E Ratio:
-1.7835
EPS:
-0.5747
Net Cash Flow:
$-102.38M
1W Performance:
-31.88%
1M Performance:
+1.50%
6M Performance:
-22.52%
1Y Performance:
-60.04%
1-Day Range:
$1.00
$1.10
1-Week Range:
$1.00
$1.50
52-Week Range:
$0.5469
$2.82
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.025 | 297.51M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
439.34 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.94 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
890.36 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.26 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.05 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte prices $50M public offering of common stock at $1.05/share - MSN
Biggest stock movers: ORCL, HUMA, and more - Seeking Alpha
Humacyte (HUMA) Phase 3 trial meets dialysis access endpoint - grafa.com
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Humacyte, Inc. Announces Underwritten Public Offering of Common Stock - Quiver Quantitative
Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing - Stock Titan
Humacyte prices $50 million public offering at $1.05 per share - Investing.com
Humacyte prices $50 million public offering at $1.05 per share By Investing.com - Investing.com Nigeria
Humacyte stock falls 6% on public offering announcement - Investing.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Benzinga
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - Yahoo Finance
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses - TradingView
Stocks to Watch : Oracle, Oxford Industries, Humacyte, PureCycle Technologies - marketscreener.com
Humacyte reports positive Phase 3 trial results for dialysis access - Investing.com
Humacyte launches public offering of common stock - Investing.com
Humacyte launches public offering of common stock By Investing.com - Investing.com Australia
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Humacyte stock falls 6% on public offering announcement By Investing.com - Investing.com Australia
[8-K] Humacyte, Inc. Reports Material Event - Stock Titan
Humacyte Announces Positive Interim Results for V012 Phase 3 Clinical Trial of Acellular Tissue Engineered Vessel in Female Dialysis Access Patients - marketscreener.com
Humacyte, Inc. Announces Proposed Public Offering Of Common Stock - TradingView
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients - The Manila Times
Humacyte reports positive Phase 3 trial results for dialysis access By Investing.com - Investing.com Canada
Biotech Humacyte plans stock sale to fund Symvess dialysis push - Stock Titan
Dialysis study: new vessel gives women 3 extra catheter-free months - Stock Titan
Humacyte (NASDAQ: HUMA) holders OK share boost, pay and auditor - Stock Titan
HUMA: All proposals, including director elections and share increase, passed with strong support - TradingView
HUMA Reiterates by BTIG -- Price Target Maintained at $2.00 - GuruFocus
Humacyte, Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Regulatory Disclosures - Minichart
Humacyte Regains Nasdaq Compliance With Minimum Bid Price - TipRanks
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Lelezard
Humacyte regains Nasdaq $1.00 bid-price compliance after May deficiency - TradingView
Humacyte (NASDAQ: HUMA) back in line with Nasdaq $1.00 bid rule - Stock Titan
HUMA Technical Analysis | Trend, Signals & Chart Patterns | HUMACYTE INC (NASDAQ:HUMA) - ChartMill
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
Benchmark raises Humacyte stock price target on dialysis launch hopes By Investing.com - Investing.com South Africa
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $2 - Moomoo
HUMA Maintained by Benchmark -- Price Target Raised to $2.00 - GuruFocus
Humacyte (HUMA) Q1 2025 Earnings Transcript - The Globe and Mail
Benchmark raises Humacyte stock price target on dialysis launch hopes - Investing.com
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis DataHas The Bull Case Changed? - Yahoo Finance
Humacyte (HUMA) Is Up 23.8% After New ATEV Self‑Repair Data And Phase 3 Timeline Update - Sahm
Humacyte, Inc. (HUMA) reports Q1 loss, misses revenue estimates - MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte appoints Todd Rasmussen as chief surgical officer By Investing.com - Investing.com Nigeria
Wall Street bulls look optimistic about Humacyte, Inc. (HUMA): Should you buy? - MSN
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy? - Yahoo Finance
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Humacyte Inc. (HUMA) Gains 3.6% as Stock Approaches Key Resistance LevelMA Crossover - thelegaladvocate.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
2.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):